BioVascular is a technology company.
BioVascular has raised $11.0M across 1 funding round.
BioVascular has raised $11.0M in total across 1 funding round.
BioVascular has raised $11.0M in total across 1 funding round.
BioVascular's investors include Pureos Bioventures.
BioVascular Inc. is a privately held biotechnology company developing drugs and devices to control intimal hyperplasia linked to vascular procedures and cardiovascular risk factors. Its lead product, saratin—a recombinant polypeptide licensed from Merck KGaA in 2005—targets hemodialysis graft access and peripheral artery grafts, with human clinical trials starting in late 2006 and early 2007, respectively.[1][3] A second product aimed at reducing a cardiovascular risk factor was slated for human studies in mid-2007.[1] The company serves healthcare providers and patients undergoing vascular interventions, addressing complications like vessel narrowing that contribute to morbidity and mortality. Classified at Series C stage with $10.87M raised (last funding 17 years ago), it remains alive but shows limited recent growth momentum, operating from San Diego with modest revenue of $405,000.[1][4]
BioVascular's backstory centers on its focus on vascular therapies, though specific founders and founding year are not detailed in available records. It emerged as a biotech player by licensing saratin from Merck KGaA in 2005, enabling rapid advancement to human trials for hemodialysis and peripheral artery applications in 2006-2007.[1][3] Early traction included initiating these trials, positioning it to tackle intimal hyperplasia—a key post-procedure issue.[1] Note that an earlier entity, Bio-Vascular, Inc., operated as a diversified medical device company developing and marketing life-improving products, but it appears distinct from the current BioVascular Inc.[2]
BioVascular rides the trend of vascular biotech innovations addressing post-procedure failures, amid rising demand for hemodialysis and peripheral artery disease treatments driven by aging populations and diabetes prevalence. Timing in the mid-2000s aligned with advances in recombinant proteins and risk-factor therapies, influencing the ecosystem by pioneering hyperplasia controls that could reduce graft failures—a persistent challenge in cardiovascular care.[1] Market forces like increasing vascular surgeries favor such targeted solutions, though its Series C status and stagnant funding post-2008 suggest limited scaling amid biotech funding shifts to immuno-oncology and gene therapies.[1][4]
BioVascular's niche in vascular hyperplasia control positions it for revival if saratin or its pipeline advances amid renewed focus on cardiovascular devices post-COVID. Trends like personalized vascular therapies and AI-driven risk prediction could reshape its journey, potentially via partnerships or acquisition by larger players in medtech. Its influence may evolve from early-stage innovator to integrated solution in graft longevity, tying back to its core mission of curbing procedure-related morbidity—watch for trial updates or funding signals to gauge momentum.[1]
BioVascular has raised $11.0M across 1 funding round. Most recently, it raised $11.0M Series C in February 2008.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2008 | $11.0M Series C | Pureos Bioventures |